Levocetirizine
- Generic Name
- Levocetirizine
- Brand Names
- Xyzal
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 130018-77-8
- Unique Ingredient Identifier
- 6U5EA9RT2O
- Background
Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.
Levocetirizine was granted FDA approval in 1995.
- Indication
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
Phase 2
Completed
- Conditions
- Cough
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT00520754
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
Not Applicable
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 459
- Registration Number
- NCT00521040
Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Institut für Atemwegsforschung GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT00439712
- Locations
- 🇩🇪
Institut für Atemwegsforschung GmbH, Düsseldorf, Nordrhein-Westfalen, Germany
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 522
- Registration Number
- NCT00421109
- Locations
- 🇧🇪
Centre nº 204, Gent, Belgium
🇦🇷Centre nº 107, Buenos Aires, Argentina
🇵🇱Centre nº 507, Krakow, Poland
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
Phase 3
Completed
- Conditions
- DermatitisEczema
- Interventions
- Drug: LevocetirizineDrug: CetirizineDrug: Placebo-CetirizineDrug: Placebo-LevocetirizineDrug: Standard topical steroid (1% hydrocortisone) ointment
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 466
- Registration Number
- NCT00375713
The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
Phase 4
Completed
- Conditions
- Hypersensitivity
- Interventions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 36
- Registration Number
- NCT00359138
Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Institut für Atemwegsforschung GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT00355771
- Locations
- 🇨🇳
Department of ORL, West China Hospital, Sichuan Hospital, Chengdu, Sichuan, China
Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 403
- Registration Number
- NCT00315523
Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- UCB S.A. - Pharma Sector
- Target Recruit Count
- 418
- Registration Number
- NCT00295022
CUTE (Chronic Urticaria Treatment Evaluation)
Phase 4
Completed
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 886
- Registration Number
- NCT00264303
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath